“MAGE-A4á¶œÂ¹ÂºÂ³Â²T for Multi-Tumor”
This study will investigate the safety and tolerability of MAGE-A4a?oA1AoA3A2T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors.
Genetic - Autologous genetically modified MAGE-A4á¶œÂ¹ÂºÂ³Â²T cells
Infusion of autologous genetically modified MAGE-A4á¶œÂ¹ÂºÂ³Â²T on Day 1
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4á¶œÂ¹ÂºÂ³Â²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors